NervGen Pharma Corp

Vancouver‑based NervGen Pharma’s stock volatility and negative P/E ratio raise caution for investors, yet its focus on spinal injury and neurodegenerative drugs shows potential value.

Explore how Vancouver‑based NervGen Pharma is driving breakthrough treatments for spinal cord injury, multiple sclerosis, and Alzheimer’s, while navigating investor‑volatility and a Canadian‑focused strategy.

Explore NervGen Pharma Corp’s bold mission to treat spinal injuries, MS, Alzheimer’s, and more, amid steep stock declines and financial challenges—what lies ahead for the Vancouver biotech startup?

NervGen Pharma Corp. has reported promising results from its Phase 1b/2a clinical trial of NVG-291, a potential breakthrough treatment for spinal cord injuries that showed increased electrical connectivity between the brain and hand muscles.

NervGen Pharma Corp is a Vancouver-based biotech company making strides in neurological therapeutics, with a promising pipeline and upcoming study results that could significantly impact the treatment of neurological disorders.

Trading in NervGen Pharma Corp’s stock has resumed on the TSX Venture Exchange after a temporary halt due to a stock circuit breaker.

NervGen Pharma Corp. is set to present promising data on its NVG-291 treatment for spinal cord injury at a major conference in June 2025.

NervGen Pharma Corp is a Canadian biotech company pioneering innovative treatments for neurodegenerative diseases, offering hope for improved quality of life for patients affected by conditions such as Alzheimer’s and multiple sclerosis.

NervGen Pharma Corp has made strategic moves, including granting stock options to directors and employees, and reported Q1 2025 financial results, positioning the company for future growth in the biotech sector.

NervGen Pharma Corp has granted 600,000 stock options to its directors and employees, as part of its strategy to incentivize leadership and workforce, with the stock price reaching a new 52-week high following the announcement.